You have 9 free searches left this month | to do more

Tipifarnib

Tipifarnib is a drug used to treat Untreated Adult Acute Myeloid Leukemia. Tipifarnib is being actively studied in 7 studies and prior, has been studied in 56.

Top SponsorsTop SitesTop Investigators
National Cancer Institute (NCI)Mayo ClinicBrigitte Widemann, M.D.
Kura Oncology, Inc.M D Anderson Cancer CenterPark, Se-Hoon
Abramson Cancer Center of the University of PennsylvaniaDana-Farber Cancer Institute
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Active, not recruiting
  • Urothelial Carcinoma
  • tipifarnib
  • Seoul, Korea, Republic of
    Samsung Medical Center
2022-03-06
Mar 6, 2022
K
Available
    • Tipifarnib
    • (no location specified)
    2021-03-18
    Mar 18, 2021
    K
    Completed
    • Leukemia, Myelomonocytic, Chronic
    • Tipifarnib
    • Scottsdale, Arizona
    • +7 more
    2021-05-12
    May 12, 2021
    K
    Completed
    • Relapsed or Refractory Peripheral T-Cell Lymphoma
    • Tipifarnib
    • Palo Alto, California
    • +12 more
    2021-04-26
    Apr 26, 2021
    N
    Completed
    • Adenocarcinoma of the Pancreas
    • +2 more
    • gemcitabine hydrochloride
    • +3 more
    • Philadelphia, Pennsylvania
      Radiation Therapy Oncology Group
    2020-10-29
    Oct 29, 2020
    S
    Recruiting
    • Non Small Cell Lung Cancer
    • Tipifarnib
    • Santiago De Compostela, A Coruña, Spain
    • +29 more
    2021-09-21
    Sep 21, 2021
    K
    Terminated
    • Myelodysplastic Syndromes
    • Tipifarnib
    • Boston, Massachusetts
    • +1 more
    2020-01-30
    Jan 30, 2020
    N
    Completed
    • Breast Cancer
    • +5 more
    • tipifarnib
    • +3 more
    • Tampa, Florida
    • +6 more
    2021-01-29
    Jan 29, 2021
    A
    Completed
    • Pancreatic Cancer
    • tipifarnib
    • radiation therapy
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    2020-04-13
    Apr 13, 2020
    K
    Completed
    • Thyroid Cancer
    • +3 more
    • Tipifarnib
    • Los Angeles, California
    • +34 more
    2021-05-12
    May 12, 2021
    N
    Completed
    • Anaplastic Large Cell Lymphoma
    • +12 more
    • Laboratory Biomarker Analysis
    • Tipifarnib
    • Iowa City, Iowa
    • +1 more
    2020-04-03
    Apr 3, 2020
    A
    Completed
    • Lung Cancer
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    2019-03-12
    Mar 12, 2019
    N
    Completed
    • Estrogen Receptor-positive Breast Cancer
    • +4 more
    • Bronx, New York
      Montefiore Medical Center
    2018-10-04
    Oct 4, 2018
    K
    Recruiting
    • HRAS Gene Mutation
    • HNSCC
    • Tipifarnib
    • HRAS Detection Assay
    • Los Angeles, California
    • +131 more
    2021-02-24
    Feb 24, 2021
    N
    Recruiting
    • Malignant Solid Neoplasm
    • +40 more
    • Tipifarnib
    • Birmingham, Alabama
    • +169 more
    2022-03-25
    Mar 25, 2022
    N
    Completed
    • Accelerated Phase of Disease
    • +6 more
    • Laboratory Biomarker Analysis
    • Tipifarnib
    • Palo Alto, California
    • +1 more
    2018-05-31
    May 31, 2018
    N
    Completed
    • Solid Neoplasm
    • Erlotinib Hydrochloride
    • +3 more
    • Rochester, Minnesota
      Mayo Clinic
    2018-05-17
    May 17, 2018
    S
    Completed
    • Brain and Central Nervous System Tumors
    • tipifarnib
    • Los Angeles, California
    • +10 more
    2018-06-22
    Jun 22, 2018
    N
    Completed
    • Adult Giant Cell Glioblastoma
    • +3 more
    • sorafenib tosylate
    • +3 more
    • Los Angeles, California
    • +6 more
    2018-05-31
    May 31, 2018
    N
    Completed
    • Advanced Malignant Neoplasm
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    2017-04-26
    Apr 26, 2017
    N
    Completed
    • Neurofibroma, Plexiform
    • Neurofibromatosis Type I
    • tipifarnib
    • placebo
    • Birmingham, Alabama
    • +11 more
    2018-03-15
    Mar 15, 2018
    N
    Terminated
    • Stage III Chronic Lymphocytic Leukemia
    • +2 more
    • tipifarnib
    • laboratory biomarker analysis
    • Cleveland, Ohio
      Case Western Reserve University
    2017-04-04
    Apr 4, 2017